Therapeutic and Toxicologic Evaluation of Anti-Lipogenic Agents in Cancer Cells Compared with Non-Neoplastic Cells

Basic and Clinical Pharmacology and Toxicology

Volumn 110, Issue 6, 2012, Pages 494-503

  Deepa, Perinkulam Ravi ^a   Vandhana, Suryanarayanan ^a,b   Jayanthi, Udayakumar ^b   Krishnakumar, Subramanian ^b  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b VISION RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CERULENIN; TETRAHYDROLIPSTATIN; TRICLOSAN;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DNA FRAGMENTATION; DRUG SAFETY; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MUELLER CELL; NONHUMAN; PRIORITY JOURNAL; RETINOBLASTOMA;

3T3 CELLS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; CELL SURVIVAL; CERULENIN; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACID SYNTHESIS INHIBITORS; FIBROBLASTS; HUMANS; INHIBITORY CONCENTRATION 50; LACTONES; MICE; NEUROGLIA; RETINAL NEOPLASMS; RETINOBLASTOMA; TIME FACTORS; TRICLOSAN;

EID: 84861331701     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00844.x     Document Type: Article

References (41)

1. Hilvo M, Denkert C, Lehtinen L, Müller B, Brockmöller S, Seppänen-Laakso T et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res 2011;71:3236-45.
2. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003;9:10-9.
3. Heiligtag SJ, Bredehorst R, David KA. Key role of mitochondria in cerulenin-mediated apoptosis. Cell Death Differ 2002;9:1017-25.
4. Liu B, Wang Y, Fillgrove KL, Anderson VE. Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells. Cancer Chemother Pharmacol 2002;49:187-93.
5. Steven JK, Fumiko A, Natasha R, Jeffrey WS. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004;64:2070-5.
6. Liao S, Umekita Y, Guo J, Kokontis JM, Hiipakka RA. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 1995;96:239-43.
7. Vázquez MJ, Leavens W, Liu R, Rodríguez B, Read M, Richards S et al. Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the beta-ketoacyl reductase reaction. FEBS J 2008;275:1556-67.
8. Brusselmans K, Vrolix R, Verhoeven G, Swinnen JV. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem 2005;280:5636-45.
9. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7:763-77.
10. Lupu R, Menendez JA. Pharmacological inhibitors of Fatty Acid Synthase (FASN) - catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?Curr Pharm Biotechnol 2006;7:483-93.
11. Bhargava HN, Leonard PA. Triclosan: applications and safety. Am J Infect Control 1996;24:209-18.
12. McMurry LM, Oethinger M, Levy SB. Triclosan targets lipid synthesis (letter). Nature 1996;394:531-2.
13. Lu S, Archer MC. Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer. Carcinogenesis 2005;26:153-7.
14. Qiao S, Tuohimaa P. Vitamin D3 inhibits fatty acid synthase expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 in prostate cancer cells. FEBS Lett 2004;577:451-4.
15. Schmidt LJ, Ballman KV, Tindall DJ. Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. Prostate 2007;67:1111-20.
16. Melamud A, Palekar R, Singh A. Retinoblastoma. Am Fam Physician 2006;73:1039-44.
17. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
18. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci U S A 1993;90:10914-21.
19. Knudsen ES, Knudsen KE. Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Exp Biol Med 2006;231:1271-81.
20. Vandhana S, Deepa PR, Jayanthi U, Biswas J, Krishnakumar S. Clinico-pathological correlations of fatty acid synthase expression in retinoblastoma: an Indian cohort study. Exp Mol Pathol 2011;90:29-37.
21. Vandhana S, Deepa PR, Aparna G, Jayanthi U, Krishnakumar S. Evaluation of suitable solvents for testing the anti-proliferative activity of triclosan - a hydrophobic drug in cell culture. Indian J Biochem Biophys 2010;47:166-71.
22. Limb GA, Salt TE, Munro PM, Moss SE, Khaw PT. In vitro characterization of a spontaneously immortalized human Müller cell line (MIO-M1). Invest Ophthalmol Vis Sci 2002;43:864-9.
23. Ming CC, Angela L, Kelly AM. Low dose docosahexaenoic acid protects normal colonic epithelial cells from araC toxicity. BMC Pharmacol 2005;5:7.
24. Menendez JA, Vazquez-Martin A, Colomer R, Brunet J, Carrasco-Pancorbo A, Garcia-Villalba R et al. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. BMC Cancer 2007;9:7.
25. Finger PT, Harbour JW, Karcioglu ZA. Risk factors for metastasis in retinoblastoma. Surv Ophthalmol 2002;47:1-16.
26. Lohmann D. Retinoblastoma. Adv Exp Med Biol 2010;685:220-7.
27. Biswas J, Das D, Krishnakumar S, Shanmugam MP. Histopathologic analysis of 232 eyes with retinoblastoma conducted in an Indian tertiary-care ophthalmic center. J Pediatr Ophthalmol Strabismus 2003;40:265-7.
28. Camassei FD, Cozza R, Acquaviva A, Jenkner A, Ravà L, Gareri R et al. Expression of the lipogenic enzyme fatty acid synthase (FAS) in retinoblastoma and its correlation with tumor aggressiveness. Invest Ophthalmol Vis Sci 2003;44:2399-403.
29. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A 1994;91:6379-83.
30. Ho TS, Ho YP, Wong WY, Chi-Ming Chiu L, Wong YS, Eng-Choon Ooi. Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells. Biomed Pharmacother 2007;61:578-87.
31. Ward WH, Holdgate GA, Rowsell S, McLean EG, Pauptit RA, Clayton E et al. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 1999;38:12514-25.
32. Ballinger A, Peikin SR. Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol 2002;440:109-17.
33. Hua ZJ, Xu M. DNA fragmentation in apoptosis. Cell Res 2000;10:205-11.
34. Huang PL, Zhu SN, Lu SL, Dai ZS, Jin YL. Inhibitor of fatty acid synthase induced apoptosis in human colonic cancer cells. World J Gastroenterol 2000;2:295-7.
35. Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE, Kuhajda FP. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 1996;56:2745-7.
36. Zuckerbraun HL, Babich H, May R, Sinensky MC. Triclosan: cytotoxicity, mode of action, and induction of apoptosis in human gingival cells in vitro. Eur J Oral Sci 1998;106:628-36.
37. Jagan NT, Michael LP, Francis PK. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-COA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 2001;285:217-23.
38. Lee JS, Lee MS, Oh WK, Sul JY. Fatty acid synthase inhibition by amentoflavone induces apoptosis and antiproliferation in human breast cancer cells. Biol Pharm Bull 2009;32:1427.
39. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A 2000;97:3450-4.
40. Orita H, Coulter J, Lemmon C, Tully E, Vadlamudi A, Medghalchi SM et al. Selective inhibition of fatty acid synthase for lung cancer treatment. Clin Cancer Res 2007;13:7139-45.
41. Liu H, Liu Y, Zhang JT. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Ther 2008;7:263-70.